How GAZYVA was studied
A clinical trial was conducted with 271 people with active lupus nephritis. Of these, 135 people received GAZYVA plus standard therapy and were compared to 136 people who received placebo plus standard therapy over 76 weeks.
The standard therapy was a combination of steroids and an immunosuppressant called mycophenolate mofetil (MMF).
The two groups were similarly sized and were made up of patients with newly diagnosed lupus nephritis, those with a prior history of lupus nephritis, and whose kidney disease ranged from mild to severe.
Nearly half of patients achieved kidney remission with GAZYVA plus standard therapy
Kidney remission is defined as a complete renal response.
of patients achieved kidney remission with GAZYVA plus standard therapy
of patients achieved kidney remission with placebo plus standard therapy
Achieving kidney remission means having low protein in the urine, maintaining kidney function, and showing no active signs of inflammation.
We know reducing steroid use matters
GAZYVA plus standard therapy may help to lower your steroid dose over time while still reducing disease activity.
of patients achieved kidney remission while reducing steroid use with GAZYVA plus standard therapy
of patients achieved kidney remission while reducing steroid use with placebo plus standard therapy
Successful steroid tapering was defined as steroids reduced to less than 7.5 mg per day.
GAZYVA plus standard therapy can help maintain kidney function
Protein in the urine, also called proteinuria, is a key sign of kidney disease in lupus nephritis. GAZYVA plus standard therapy may help lower proteinuria and keep your kidneys working.
Higher proteinuria = more kidney damage.
In a clinical trial, 56% of patients who received GAZYVA plus standard therapy had reduced proteinuria (reduced amount of protein in the urine) vs 42% of patients who received placebo plus standard therapy.
EULAR 2025 Guidelines recommend early use of GAZYVA
There are research-backed guidelines that help your doctor to make informed decisions about treatments for lupus nephritis.
EULAR 2025 Guidelines recommend GAZYVA as an option in combination with standard therapy for patients with active lupus nephritis, especially those at high risk of getting worse.
Exploratory results
Fewer patients had flares with GAZYVA plus standard therapy vs placebo plus standard therapy
A flare refers to a period of time when your lupus nephritis symptoms suddenly get worse. Flares can cause more damage to your kidneys.
In a clinical trial, patients receiving GAZYVA had fewer flares from Week 24 through Week 76
of patients who received GAZYVA plus standard therapy had flares
of patients who received placebo plus standard therapy had flares
The data presented here are exploratory, meaning there are limitations with these data. “Exploratory” is a way to describe data when researchers do not make a formal comparison between treatments to determine a definitive benefit. Your experiences may differ from the results. Talk to your doctor about how to best understand these results.
Studied in a diverse population
GAZYVA plus standard therapy was studied in a diverse group of people, including those at different stages of lupus nephritis—some with milder disease and others with more serious kidney damage. This included patients from Hispanic or Latino, American Indian or Alaska Native, Black or African American, Asian, and White backgrounds.
You only live once—give your kidneys the care they deserve with GAZYVA.
Prepare for your doctor’s visit
Download this doctor discussion guide for tips, questions, and more, so you can make the most of conversations with your doctor.
Patient Resource Center
Call our Patient Resource Center
This is not meant to replace the advice of your healthcare team.
-
Lupus nephritis
A type of kidney disease caused by lupus. The immune system attacks the kidneys, causing inflammation and damage.
-
Mycophenolate mofetil (MMF)
A medicine used to treat lupus nephritis. It is often part of standard or advanced therapy.
-
Standard therapy
A treatment that uses 2 types of medicine, usually a steroid and an immunosuppressant like MMF (mycophenolate mofetil), to manage lupus nephritis.
-
Kidney remission
Having low protein in the urine, maintaining kidney function, and showing no active signs of inflammation.
-
Steroids
Medicines that reduce inflammation but can cause side effects when used in high doses for a long time